World Journal of Surgery

, Volume 34, Issue 7, pp 1481–1487 | Cite as

Regulatory T Cells in Peripheral Blood, Lymph Node, and Thyroid Tissue in Patients with Medullary Thyroid Carcinoma

  • S. Müller
  • D. Poehnert
  • J. A. Müller
  • G. W. F. Scheumann
  • M. Koch
  • R. Lück
Article

Abstract

Background

Immunological response of the human body is controlled by the suppressive characteristics of regulatory T cells (Tregs). In various diseases a change in the number of Tregs is evident. For example, whereas Tregs are reduced in auto-immunological processes, an increase of Tregs is found with various malignant tumors. Regarding medullary thyroid carcinoma (MTC) no such studies have been performed to date.

Methods

Expression of CD4 and CD25 in CD45+ leukocytes from blood and lymph nodes was studied by flow cytometry in patients with MTC and patients with benign goiter. We also examined the marker forkhead box P3 (FoxP3), an intracellular transcription factor, which is supposed to be the most specific marker for Tregs. Immunohistochemical staining for FoxP3 was performed on lymph node and thyroid tissue.

Results

The number of FoxP3+ lymphocytes in peripheral blood was significantly higher in patients with MTC than in controls (p = 0.02). This result was confirmed immunohistochemically in lymph node and thyroid tissue, as well as in carcinoma tissue. No difference in CD4+CD25+ lymphocytes was observed between the two groups. After clinical staging (International Union against Cancer—UICC—stages) of MTC patients, triplication of FoxP3+ lymphocytes could be observed from MTC < UICC II to MTC > UICC II.

Conclusions

An increase of FoxP3+ lymphocytes could be shown in peripheral blood of patients with MTC but not in patients with benign goiter; this increase also correlates with findings in lymph nodes and thyroid gland. The number of FoxP3+ cells correlated with the patients’ prognosis. Therefore, FoxP3+ lymphocytes are a good diagnostic criterion for malignancy in patients with medullary thyroid carcinoma, and their presence at staging may influence therapeutic decisions.

Notes

Acknowledgments

S. Müller was supported by the Strukturierte Doktorandenausbildung—StrucMed from Hannover Biomedical Research School.

References

  1. 1.
    Horwitz DA, Zheng SG, Wang J et al (2008) Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp3+CD4+ Treg. Eur J Immunol 38:912–915CrossRefPubMedGoogle Scholar
  2. 2.
    Kryczek I, Liu R, Wang G et al (2009) FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 69:3995–4000CrossRefPubMedGoogle Scholar
  3. 3.
    Imai H, Saio M, Nonaka K et al (2007) Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 98:416–423CrossRefPubMedGoogle Scholar
  4. 4.
    Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949CrossRefPubMedGoogle Scholar
  5. 5.
    Liyanage UK, Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761PubMedGoogle Scholar
  6. 6.
    Ling KL, Pratap SE, Bates GJ et al (2007) Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immunol 7:7Google Scholar
  7. 7.
    Vikman S, Sommaggio R, De La Torre M et al (2009) Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue. Acta Oncol 48:391–400CrossRefPubMedGoogle Scholar
  8. 8.
    Frilling A, Liedke M-O (1998) Medulläres Schilddrüsenkarzinom: Sporadisch/Familiär. Wann und warum ein Screening? Internist 39:588–591CrossRefPubMedGoogle Scholar
  9. 9.
    Eng C, Clayton D, Schuffenecker I et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575–1579CrossRefPubMedGoogle Scholar
  10. 10.
    AWMF-Leitlinien-Register: Therapie maligner Schilddrüsentumoren Nr. 032/014Google Scholar
  11. 11.
    Skinner MA, Moley JA, Dilley WG et al (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353:1105–1113CrossRefPubMedGoogle Scholar
  12. 12.
    Niccoli-Sire P, Murat A, Rohmer V et al (2003) When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? Surgery 134:1029–1036 discussion 1036–1037CrossRefPubMedGoogle Scholar
  13. 13.
    Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671CrossRefPubMedGoogle Scholar
  14. 14.
    Hinz S, Pagerols-Raluy L, Oberg HH et al (2007) Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67:8344–8350CrossRefPubMedGoogle Scholar
  15. 15.
    Niederkorn JY (2008) Emerging concepts in CD8+ T regulatory cells. Curr Opin Immunol 20:327–331CrossRefPubMedGoogle Scholar
  16. 16.
    Roberts SJ, Ng BY, Filler RB et al (2007) Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci USA 104:6770–6775CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2010

Authors and Affiliations

  • S. Müller
    • 1
  • D. Poehnert
    • 1
  • J. A. Müller
    • 2
  • G. W. F. Scheumann
    • 1
  • M. Koch
    • 3
  • R. Lück
    • 1
  1. 1.Allgemein-, Viszeral- und TransplantationschirurgieMedizinische Hochschule HannoverHannoverGermany
  2. 2.Klinik für NuklearmedizinMedizinische Hochschule HannoverHannoverGermany
  3. 3.Hepatobiliäre Chirurgie und TransplantationschirurgieUniversitätsklinikum Hamburg-EppendorfHamburgGermany

Personalised recommendations